A federal judge has approved multiple classes in litigation accusing Indian generic drugmaker Ranbaxy Laboratories of delaying the launch of generic drugs by submitting false applications to US regulators.
In an opinion issued Friday, May 14, US District Judge Nathaniel Gorton in Boston certified classes of both direct purchasers, including drug wholesalers, and indirect purchasers, such as health plans and insurance companies.
“We look forward to trial in January 2022,” said Thomas Sobol of Hagens Berman Sobol Shapiro, a lawyer for the direct purchasers.
India’s Sun Pharmaceutical Industries, which acquired Ranbaxy in 2014, and Devora Allon of Kirkland & Ellis, a lawyer for Ranbaxy, did not immediately respond to requests for comment. Nor did Gerald Lawrence of Lowey Dannenberg, a lawyer for the indirect purchasers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkey Fines Meta $10.4 Million for Abusing Market Dominance
May 6, 2024 by
CPI
Canadian Watchdog Launches Inquiry into Lululemon’s Greenwashing Practices
May 6, 2024 by
CPI
Massachusetts Supreme Court Deliberates Ballot Redefining Gig Worker Status
May 6, 2024 by
CPI
European Commission Approves Nippon Steel’s $14.9 Billion Buyout of U.S. Steel
May 6, 2024 by
CPI
Banco Sabadell Rejects Rival BBVA Merger Proposal
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI